Table V.

Adverse events.

CTCAE ver. 3.0 grade	BBP− (n=27)						BBP+ (n=15)
	1, n	2, n	3, n	4, n	All, %	≥G3, %	1, n	2, n	3, n	4, n	All, %	≥G3, %
Leucopenia	4	2	1	0	25.9	3.7	1	6	1	1	60.0	13.3
Neutropenia	1	3	2	0	22.2	7.4	1	6	1	1	60.0	13.3
Anemia	5	2	3	0	37.0	11.1	4	1	0	0	33.3	0.0
Thrombocytopenia	4	0	0	0	14.8	0.0	3	1	0	0	26.7	0.0
Diarrhea	5	8	2	0	55.6	7.4	5	2	0	0	46.7	0.0
Anorexia	3	7	2	0	44.4	7.4	5	2	0	0	46.7	0.0
Nausea	5	7	0	0	44.4	0.0	4	4	0	0	53.3	0.0
Vomiting	1	6	0	0	25.9	0.0	3	0	0	0	20.0	0.0
Fatigue	2	4	2	0	29.6	7.4	3	1	0	0	26.7	0.0
Stomatitis	1	0	0	0	3.7	0.0	1	0	0	0	6.7	0.0
Dizziness	0	0	0	0	0.0	0.0	0	0	0	0	0.0	0.0
Neuropathy	8	2	0	0	37.0	0.0	4	1	0	0	33.3	0.0
Alopecia	5	5	1	0	40.7	3.7	3	6	0	0	60.0	0.0
Hand-foot syndrome	6	1	0	0	25.9	0.0	3	0	1	0	26.7	6.7
Proteinuria	0	0	0	0	0.0	0.0	0	0	0	0	0.0	0.0
Hypertension	0	1	2	0	11.1	7.4	2	3	3	0	53.3	20.0
Bleeding	0	0	0	0	0.0	0.0	0	0	0	0	0.0	0.0

BBP, bevacizumab beyond progression; CTCAE, Common Terminology Criteria for Adverse Events.